Activity-based cost analysis of hepatic tumor ablation using CT-guided high-dose rate brachytherapy or CT-guided radiofrequency ablation in hepatocellular carcinoma

10Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: To analyse and compare the costs of hepatic tumor ablation with computed tomography (CT)-guided high-dose rate brachytherapy (CT-HDRBT) and CT-guided radiofrequency ablation (CT-RFA) as two alternative minimally invasive treatment options of hepatocellular carcinoma (HCC). Materials and methods: An activity based process model was created determining working steps and required staff of CT-RFA and CT-HDRBT. Prorated costs of equipment use (purchase, depreciation, and maintenance), costs of staff, and expenditure for disposables were identified in a sample of 20 patients (10 treated by CT-RFA and 10 by CT-HDRBT) and compared. A sensitivity and break even analysis was performed to analyse the dependence of costs on the number of patients treated annually with both methods. Results: Costs of CT-RFA were nearly stable with mean overall costs of approximately 1909 €, 1847 €, 1816 € and 1801 € per patient when treating 25, 50, 100 or 200 patients annually, as the main factor influencing the costs of this procedure was the single-use RFA probe. Mean costs of CT-HDRBT decreased significantly per patient ablation with a rising number of patients treated annually, with prorated costs of 3442 €, 1962 €, 1222 € and 852 € when treating 25, 50, 100 or 200 patients, due to low costs of single-use disposables compared to high annual fix-costs which proportionally decreased per patient with a higher number of patients treated annually. A break-even between both methods was reached when treating at least 55 patients annually. Conclusion: Although CT-HDRBT is a more complex procedure with more staff involved, it can be performed at lower costs per patient from the perspective of the medical provider when treating more than 55 patients compared to CT-RFA, mainly due to lower costs for disposables and a decreasing percentage of fixed costs with an increasing number of treatments.

Figures

  • Table 1 Procedural steps and involvement staff of both ablation methods
  • Table 1 Procedural steps and involvement staff of both ablation methods (Continued)
  • Table 2 Expenditures for disposables used in CT-RFA and CT-HDRBT
  • Fig. 1 Magnetic resonance imaging scan of a 69-year-old patient with liver cirrhosis and hepatocellular carcinoma in liver segment III (a, arrow). The tumor was treated by CT-guided high-dose rate brachytherapy with a single catheter and a tumor-enclosing target dose of 20 Gy (b). Six weeks later, complete tumor ablation is indicated by a surrounding lack of uptake of hepatocyte-specific contrast medium (Primovist™, Bayer Healthcare, Leverkusen, Germany) (c, arrow)
  • Fig. 2 A 65-year-old patient with cirrhosis and a hypervascularized, subcapsular hepatocellular carcinoma in liver segment III (a, arrow). The tumor was ablated in a single session with 110 W over 15 min (b). The contrast-enhanced control scan obtained immediately afterwards shows complete necrosis of the ablated area with a hypervascular rim (c, arrow)
  • Table 3 Costs for equipment for CT-HDBRT and CT-RFA
  • Fig. 3 Results of a sensitivity analysis comparing costs of CT-HDRBT and CT-RFA in relation to the number of patients treated with either method per year. The break-even is reached at 55 treated patients per year, when calculated costs of CT-HDRBT fall below the costs of CT-RFA. At this point, calculated costs for CT-RFA are 1,841.92 € and 1,827.89 € for CT-HDRBT, and costs for CT-HDRBT decrease further as the number of treated patients increases, whereas costs for CT-RFA remain nearly stable

References Powered by Scopus

Hepatocellular carcinoma

3976Citations
N/AReaders
Get full text

Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices - Modeling studies

974Citations
N/AReaders
Get full text

Early-stage hepatocellular carcinoma in patients with cirrhosis: Long-term results of percutaneous image-guided radiofrequency ablation

749Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Image-guided high-dose-rate brachytherapy of malignancies in various inner organs-technique, indications, and perspectives

43Citations
N/AReaders
Get full text

Critical review of multidisciplinary non-surgical local interventional ablation techniques in primary or secondary liver malignancies

14Citations
N/AReaders
Get full text

The dosimetric impact of replacing the TG-43 algorithm by model based dose calculation for liver brachytherapy

11Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Schnapauff, D., Collettini, F., Steffen, I., Wieners, G., Hamm, B., Gebauer, B., & Maurer, M. H. (2016). Activity-based cost analysis of hepatic tumor ablation using CT-guided high-dose rate brachytherapy or CT-guided radiofrequency ablation in hepatocellular carcinoma. Radiation Oncology, 11(1). https://doi.org/10.1186/s13014-016-0606-x

Readers over time

‘16‘18‘19‘20‘21‘22‘23‘24‘2502468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 4

44%

Researcher 3

33%

Professor / Associate Prof. 1

11%

Lecturer / Post doc 1

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

67%

Nursing and Health Professions 2

13%

Economics, Econometrics and Finance 2

13%

Pharmacology, Toxicology and Pharmaceut... 1

7%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 53

Save time finding and organizing research with Mendeley

Sign up for free
0